| Open Document File Size: 15,85 KBShare Result on Facebook
City DUBLIN / / Company Astex Pharmaceuticals Inc. / Astex Pharmaceuticals Astex Pharmaceuticals / Astex Pharmaceuticals / / Country United States / / Event FDA Phase / / Facility US National Cancer Institute / / IndustryTerm treatment of non small cell lung cancers / pharmaceutical / / MedicalCondition tumor / different tumor / cancer / disease / castration-resistant prostate cancer / refractory gastrointestinal stromal tumors / hematological malignancies / non small cell lung cancers / solid tumors / gastrointestinal tumors / melanoma / prostate cancer / breast cancer / / MedicalTreatment hormone therapy / / Organization US National Cancer Institute / / Person James S.J. Manuso / Mohammad Azab / / Position chief medical officer / chairman & chief executive officer / / Product Herceptin / Gleevec / Iressa / AT13387 / Dacogen / Tarceva / AT13387-04 / HSP90 / / ProvinceOrState California / / Technology pharmacokinetics / pharmacodynamics / / URL http /
SocialTag |
September 10, 2012 Astex Pharmaceuticals Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in Prostate Cancer Patients DUBLIN, Calif., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq: